The distribution of IDH1/IDH2 mutations was highly variable among these three subgroups: 33% of IDH-mutant among secondary-type t-AMLs; 8.5% of IDH-mutant among TP53-mutated t-AMLs; 10% of IDH-mutant among de novo/pan-AML t-AML [79]. The gene discussed is TP53; the disease is acute myeloid leukemia.